Transcript: Pfizer Pfizers first product was in 1849 it was an anitparasitic to help fight intestinal worms which were really common in the 19th century The company has grown from a local group in williamsburg to more than 84,000 employees in over 90 countries all over the world. Pfizer is a pharmaceutical company that ranks #1 in sales in the world making $16.5 Billion in only the fist quarter of 2011, and is worth $130 billion Pfizers most famous drug is viagra, but it's best selling drug is lipitor which is also the best selling drug in america which is a drug that helps lower cholesterol. The current CEO is Ian Read, the board promoted him when the last ceo,Jeffrey kindle abruptly resigned Pfizers corporate headquarters is located in New york city Pfizers vision is to achieve and sustain it's leading place as the world's premier research-based pharmaceutical company. Pfizers mission statement is : We will become the world's most valued company to patients, customers, colleages,investors business partners, and the communities where we work and live Pfizer also collaborates with other companies for example Pfizer and Bristol-Myers Squibb (BMS) are working together to develop a medecine that helps prevent and treat blood clots from forming Pfizer ranks 36 in Forbes Global 2000 list Pfizers shares were made a component of Dow Jones Industrial average on April 8, 2004 In 2006 Pfizer sold its consumer healthcare unit to Johnson & Johnson for 16.6 Billion Dollars If i had to work for pfizer i would work as a researcher to help develop new medecine to fight cancer and other life threatening diseases In 2009 Pfizer bought pharmaceutical giant Wyeth for $68Billion Pfizer also makes medecine for both pets and farm animals Pfizer is currently shutting down a viagra plant in europe laying off 2400 people to meet its $1.2 billion budget slash Pfizer was named the most respected pharmaceutical company in ecuador in 2006 and 2007 Pfizer was founded in 1849 by Charles Pfizer and Charlse Erhart, they first started out in a modest brick building in Williamsburg, Virginia
Transcript: Pfizer Cow/Calf Producer Feedlot Meat packer Customer/Retailer Pfizer Power Balance Influx beef production in the USA Price inversely propotional to production Power Balance in the buyer/seller relationships Stint on animal health products Shift to a lower cost alternative Threat to Pfizer Suggested Supply chain Sponsoring Label of Quality Promotions Relationships with ranchers Consumers Meat consumer Premium price for Pfizer products of Christopher Supply chain Feedlot Concentration Baptiste Animal Healthcare Meatpackers charged to the customers Recommendations Distributors/ Dealers Dairy High prices Recommandations Medicaments Suggested supply chain paid to ranchers Cow/Calf Power Balance Mohcine Meatpacker Supply chain Prices Low prices Vouchers Meat producer < Veterinarians Branded beef Costs Pfizer tracking server Pfizer Julia & Adam
Transcript: Prevnar-13 Presentation By: Cade Morgan Presentation Agenda Presentation Agenda: PREVNAR-13 OVERVIEW PATIENT MARKET VALUE PROPOSITION Prevnar-13 Overview Prevnar-13 Overview- Prevnar-13 is approved for adults 18 years or older to help combat/prevent Pneumococcal Pneumonia caused by the 13 Streptococcus Pneumonia strains included in the vaccine. Approved as a single-dose, packaged as a pre-filled syringe, and the tip cap and rubber plunger are not made with natural rubber latex. Prevnar-13 is administered intramuscalurly (in four shots) and costs anywhere from $175.00-$235.00 per dose without coverage or coupons. Patient Impact Patient Market- Pneumococcal infection is spread when an infected person talks, coughs or sneezes small droplets containing infectious agents into the air. The droplets in the air may be breathed in by those nearby. Infection may be spread by contact with hands, tissues and other articles soiled by infected nose and throat discharges. It is estimated that about one million US adults get Pneumococcal Pneumonia each year, as many as 400,000 hospitalizations from Pneumococcal Pneumonia occur annually in the US, and about 5-7% of those who are hospitalized from it will die. Pneumococcal Pneumonia can infect the upper respiratory tract and can spread to the blood, lungs, middle ear, or nervous system. Also, Pneumococcal Pneumonia mainly causes illness in children younger than 5 years old and adults 65 years of age or older. Value Proposition Value Proposition- About 5 to 7 percent of people who need care in a hospital due to Pneumococcal Pneumonia die from it. Fewer will get Pneumococcal Meningitis or Sepsis, but the mortality rate among adults is higher (20 percent or more). Most (>95 percent) Pneumococcal deaths in the United States are in adults. More than 291 million (95% uncertainty level, 276.3 million-307 million) LRI episodes occurred in 2015. Among them, 101.8 million (95% UI, 90 million-114.4 million) were reported in children aged younger than 5 years. The most common etiology was Pneumococcal Pneumonia, which was responsible for 1,517,388, or 55.4%, of all LRI deaths. A study showed one dose of PCV13 protects 8 in 10 babies from invasive disease caused by vaccine serotypes. This protection was similar among children with and without medical conditions that put them at increased risk of Pneumococcal disease. With competitors like Merck and Co. looming to make a major impact the market, Pfizer's Prevnar-13 will need to stay competitive in terms of price, marketing, and product/indication differentiation to stay at the top of the vaccine space.
Transcript: Specific Questions: Presented By: In reaction to the difficult times in 2007, Pfizer laid off 10,000 employees or roughly 1/10th of it’s workforce. The lay-off eliminated 1/5th of the sales force in Europe and in the US, and shut down multiple research centers and factories. Research was reorganized to focus only on five main areas. CEO Kindler demanded collaboration from independent researchers, and simultaneously put the company’s research initiatives online for all to see. Initially, the company’s stock price fell in reaction to the employee lay-offs, and prices dropped from roughly $26.00/share in 2007 to roughly $15.00/share in 2008. The stock price remained low, but steady until 2010, when it began to rise again. In February of 2015, Pfizer’s stock price reached a new high of $34.00/share. Case Specific Questions Threat of Rivalry - High Threat of Substitutes - Moderate API (Active Pharmaceutical Ingredient) Manufacturers Contracts Switching Costs Pfizer: Then The company produced tartaric acid and cream of tartar in 1862, expanding to meet the needs of the Union Army during the Civil War. Growth continued due to high demand, and Pfizer became one of the largest producers of citric acid for consumer beverages in 1880. Erhart died in 1891, and Pfizer became the sole owner of the company. In 1905 Emile Pfizer became president of the company and Charles Pfizer died in 1906. After breakthroughs In 1936, the company became a large producer of vitamins. In 1941, Pfizer produced five times more penicillin than originally anticipated, due to their unique fermenting method. The company was the only producing the "miracle drug" in this way. -Will collaborative research, acquisition of other companies, and streamlining existing operations prove effective? -Can Pfizer be effective moving into the US$500 million drugs market? -Should Pfizer invest in R&D of generics to compete with others? Porter's 5 Forces 2 Threat of Suppliers - High The company was founded in 1849 by two cousins, Charles Pfizer, a chemist, and Charles Erhart, a confectioner. With a $2500 loan from Pfizer’s father, the company started in Brooklyn, NY as a fine chemicals business. Pfizer later became a huge manufacturer of newly discovered Penicillin, discovered new ways to produce vitamins, and later became a world leader in pharmaceutical research and AIDS education and prevention. Proposed Recommendations -Collaborative Research: Horizontal contracting -Product Refinement: Streamlining of Existing Products -Product Mix: Innovative Pharmaceuticals, Generics, OTC and Vaccines -Pfizer would like to re-position itself so that no singl drug will account for more than 10% of the company's revenue. Currently, Lipitor is accounting for 25% of the revenue -Horizontal integration and collaboration in order to reduce R&D overhead costs and increase efficiency Julian, Mallory, Matthew, Toni and Janae 1)What is your assessment of the pharmaceutical industry at the time of the case? How is competition changing? What factors are driving the changes? Ans: The pharmaceutical industry is both emerging and mature at the time of the case. It is emerging in the sense that there are constantly new areas for growth potential with the never-ending rise of new disease, but it is also a mature industry that has been around for a long time. There are not many competitors in this industry, but the few that exist are large. At the time of this case, the industry is dealing with decreasing revenues due to competition and government influences on price in Europe. Competitors in this industry are acquiring and merging with competing firms. 2)What will competition in pharmaceuticals look like in 10 years? Ans: There is going to be a significant rise in the number of aging population and in the number of people who can afford to purchase medication. A lot more terminal diseases will be treatable with medications and, therefore, become chronic, which will demand a sustained reliance on prescription medications. There will be growth opportunities to develop drugs for drug-resistant strains of illnesses. There will also be a rise in the number of generics produced due to the expiring on numerous patents. There will also be a sharp drop in revenues due to the adoption of universal health care in countries such as China, Germany, India, and Brazil. 3)What are the keys to success in this industry? The keys to success in this industry are to develop drugs that can compete and be profitable in increasingly price regulated markets. Success will also hinge on the ability of firms to cut R&D costs through identifying and discontinuing non-successful projects early on. The ability to quickly develop blockbuster drugs to combat new disease strains will also be a factor to success. Proposed Strategies Pfizer was the undisputed market leader. Primary Competitors- GlaxoSmithKline, Sanofi-aventis, and Novartis ****Holly mentioned in class Wednesday that we did not need a separate slide to
Transcript: 1928 - Pfizer chemist invents Penicillin Age discrimination lawsuits Compensation disputes Unsafe working conditions Community Performance Innovation Donated $2.9 million to Western Michigan University Donated $20 million to tsunami victims 2009 - Pfizer merges with Wyeth l Community Pfizer 81,800 employees $50 billion in revenue Headquarters in New York Mission Customer Focus Greener packaging and supply chain operations Compliance Program From Trial and Error to Trial and Terror Leadership Liar, Liar cries the Buyer! Integrity Working to reduce greenhouse gas emissions Stockholder Information Lied about side effects of Lipitor Used influence to change guidelines in their favor Illegal sales and marketing campaign Collaboration 1950 - Pfizer pharmaceutical sales force is formed Pfizer is founded in 1849 Internal Relations Laws Sued by the Nigerian government for unethical testing on humans 1919 - Revolutionizes fermentation process Respect for People Geez Louise, now the Employees?? Level of Corporate Ethical Development Level of Corporate Social Responsibility Recommendations HIV/AIDS Foundation called Connect HIV Shoot...did we pollute? Pfizer Today "We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live." Pfizer Commitment to Community Top emitters of toxic pollutants in industry Investigated for lack of control and monitoring Quality Pfizer's Values Conclusion Donated $1.4 million to Haiti earthquake victims
Transcript: My Road, My Journey The Past These places and roles taught me the valuable lessons that paved my way to this moment Past Bronson Battle Creek Hospital Staff Assistant Bronson Battle Creek Hospital Established new position Trained employees on new electronic medical records (EMR) software Something that works for one team does not always work for another team Summit Pointe Autism Center Behavior Technician Summit Pointe Autism Center Apply behavioral principles to increase positive behaviors and decrease negative behaivors Performance matrix and monetary incentives "If you pit a good performer against a bad system, the system will win almost everytime." -Rummler & Brache Here and Now Great Lakes Center for Autism Treatment and Research (GLC) Present External Systems Analysis Consultant EMR 2.0 Authorization and billing process Workflow Analysis Cross-functional process mapping using Lucidchart software Integration of new EMR Proactive instead of reactive Residential Opportunities Inc. Pre-Strategic Planning Pre-Strategic Planning Developed a tool to facilitate business strategy discussion and pinpoint knowledge and data gaps Worked closely with ROI's top executive leaders Registered Behavior Technicians (RBT) Training Development Training Development Meets the requirements of the national certification board (BACB) Personalized to accomodate the specific needs of the organization Training environments match natural work conditions What's in store? Future Continuous Improvement Diagnosing issues Creating Solutions Data Analysis/Visualization Lean Six Sigma
Transcript: Introduction I will be shadowing Anamaria Jorga as she prepares for the Tanezunab Advisory Board in October 2013. Although there will be few actual "assignments", I will learn by observing the necessary motions involved with organizing a large-scale meeting with experts. I would like to have all of the research completed by July 24th, 2013. Expected Date of completion: August 9th, 2013 Assignments 1. Pain Narrative Reference Compilation (Marina Brodsky) 2. Pain Inventory (Steve and Margaret) 3. The History of Pain and Pfizer (Steve) 4. Tanezunab Advisory Board (Anamaria) Pain Narrative Reference Compilation Acquired all of the PDFs for the April 2013 Pain Narrative Slide Deck by reaching out to SuEllen from The HWP Group (vendor), and the majority of the PDFs of the resources used in the November 2012 Pain Narrative Script. Organized the files to have the Author, the Year of publication, and a few key terms from the Title for easy "searchability". PDFs have been put into a folder, and that folder will go on the Pain Inventory Sharepoint site. I have used Endnote to create citations for the resources, and I will be linking the PDFs to the citations in a Word document. The point of the assignment is to create a tool that will allow members of the Pain Team to access these resources. Expected date of completion: July 2nd, 2013 The goal is create a "one stop shop" for all documents, links, and resources relevant to the Medical Affairs Pain Team. I have interviewed all of the MAPLs and Marina about what they would like to have access to - results include the Pain Narrative references, past Advisory Board slide decks, market research results, and past and present operation plans, as well as useful Above Brand information. This information will be put on a Sharepoint. Expected date of completion: July 24, 2013 Diana Tive's Summer at Pfizer The History of Pain Products at Pfizer Tanezunab Advisory Board Assistance Because of my interest in History, I have been assigned the task of constructing a written history of Pain Products that Pfizer has either created or acquired. I will obtain this information through research and interviews with various people on the Pain team. It is my belief that this information will be useful to the Pain Team as a way of comprehending how the company got to where it is today in terms of its Pain products. Pain Inventory Diana Tive - Medical Affairs Pain Team Intern for Summer 2013 - June 3rd - August 9th - Sponsors: Stephen Watt and Margaret Essex - Rising Junior at Bryn Mawr College in Bryn Mawr, PA
Transcript: Ukraine Poland Outgoing Global Community Development Program 2014 WWII 7 People from 9 Universities in Europe A total of 1150 Life Changing Experience through our Exchange Programs Italy Poverty Reduction 4000 + Applicants 320 went on internships Thank you The world's LARGEST youth driven organization 15 + Nationalities 2015 Goals Entrepreneurship AIESEC 200 + Projects We envision Education China Incoming Global Community Development Program Czech Republic 346 interns 2014 EIGHT different Projects Tourism Promotion A total of 150 + Impactful Experience through Team Member and Team Leaders Program Human Rights Malaysia Health Awareness Brazil India Romania Russia Turkey
Description: A well-organized training presentation template is a critical tool for education professionals. From roadmaps to reviews, this training template will help you take your next EDU training presentation to the top of the class.
Description: Impactful presentations need stunning visuals and a meaningful metaphor to show high-level concepts and the smaller details. This customizable presentation template uses a classic world map visual to help you navigate complex information while staying grounded in your presentation’s core message.
Description: Structuring your syllabus doesn't have to be a huge headache with this customizable lesson plan presentation template. With a classic chalkboard theme and adaptable structure, it's easy to add new subjects, assessments, assignments, and more.
Description: Show the big picture, zoom in on details, and explain clearly how it all relates with this Prezi executive brief or Prezi nonprofit template. The lively image and bold colors make it easy to create compelling, engaging executive brief or nonprofit presentations.
Now you can make any subject more engaging and memorable